The Takeda ORZEYFUL launch is now underway in the United States. On November 12, 2026, Takeda (TSE:4502/NYSE:TAK) announced that ORZEYFUL™ (oveporexton) CIV is available by prescription for adults with narcolepsy type 1 (NT1, narcolepsy with cataplexy). The company calls it the first and only orexin agonist for this patient community.
According to Takeda, ORZEYFUL is a first-in-class orexin medicine that treats the disease holistically by targeting the underlying orexin deficiency associated with NT1. The company says it has the potential to redefine the standard of care. That is Takeda’s own framing and a forward-looking statement, so readers should treat it as the company’s expectation rather than an established outcome. The Takeda ORZEYFUL launch follows an August 2026 U.S. Food and Drug Administration decision that was pending controlled substance classification.
ORZEYFUL has since been classified as a schedule IV controlled substance, which is why the product name carries the CIV designation. It is available from licensed healthcare providers and will be dispensed across the U.S. through Accredo Specialty Pharmacy, part of Evernorth Health Services. Takeda also offers patient support programs to help eligible adults get started, including help understanding coverage steps and connecting to assistance options.
What the Takeda ORZEYFUL Launch Means for Adults With Narcolepsy Type 1
NT1 is a rare, chronic neurological disease driven by a loss of orexin. Takeda estimates it affects about 3 million people worldwide and 120,000 in the U.S. The condition is characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), cognitive symptoms and disrupted nighttime sleep that can affect work, education and social relationships. In Takeda’s description, the Takeda ORZEYFUL launch offers a treatment that targets the underlying orexin deficiency rather than individual symptoms.
Takeda also points to unmet need. More than half of treated NT1 patients remain symptomatic, according to the company. NT1 is also significantly underdiagnosed, with only an estimated 50% diagnosed in the U.S., and the diagnostic process can take an average of 10 years. Takeda attributes the gap partly to symptom overlap with other sleep-wake and comorbidity disorders and to limited easy-to-use diagnostic tools.
Emily P., a clinical trial participant with NT1, said in the release that her narcolepsy has become more manageable and that she feels more confident planning her day. Hers is an individual account and not a measure of average results.
How ORZEYFUL Works: The Science Behind the Takeda ORZEYFUL Launch
ORZEYFUL (oveporexton) is an oral orexin receptor 2 (OX2R) agonist. It selectively stimulates OX2R to restore signaling and address the underlying orexin deficiency associated with NT1. Takeda says that by activating these receptors the medicine promotes wakefulness and reduces abnormal REM-sleep-like phenomena, including cataplexy. It is said to address a range of daytime and nighttime symptoms as evaluated in clinical studies and consistent with the approved label.
The U.S. indication is specific: treatment of narcolepsy type 1 in adult patients. The Takeda ORZEYFUL launch therefore does not cover narcolepsy type 2, idiopathic hypersomnia or pediatric use. Takeda notes that ORZEYFUL has been approved by regulatory bodies in China, Japan and the United States for NT1.
Dr. Emmanuel Mignot, principal U.S. investigator in the ORZEYFUL Phase 3 program, said he can now start a new conversation with patients about this treatment approach. Rhonda Pacheco, president of Takeda’s U.S. Business Unit, said the company is equally focused on supporting care and access for patients prescribed the medicine. Her remarks suggest access support will be a central part of the Takeda ORZEYFUL launch.
Safety Profile and Prescribing Considerations in the Takeda ORZEYFUL Launch
The prescribing information carries several warnings. In pooled Phase 3 studies in NT1, insomnia occurred in 60% of patients on 2 mg twice daily, 55% on 1 mg twice daily and 1% on placebo. Prescribers are told to inform patients about insomnia risk before starting. They should consider dose reduction or discontinuation if insomnia persists beyond 7 days and significantly affects daytime functioning or quality of life.
Urinary effects are also prominent. Urinary frequency occurred in 58%, 53% and 5% of patients in the 2 mg, 1 mg and placebo groups, while urinary urgency occurred in 16%, 15% and 1%. The label links these symptoms to OX2R agonism on central micturition pathways. It advises screening before treatment and monitoring patients with a history of overactive bladder. Clinicians following the Takeda ORZEYFUL launch will need to counsel patients on these effects early.
Asymptomatic creatine phosphokinase (CPK) elevations above five times the upper limit of normal were seen in 11% (21/196) of treated patients versus 5% (4/76) on placebo. Two cases involved markedly elevated CPK and transaminase levels, and both patients discontinued treatment. None was associated with myoglobinuria or renal impairment. Patients should report unexplained muscle pain, weakness or dark urine. The most common adverse reactions, at 5% or more and above placebo, were insomnia, pollakiuria, micturition urgency and salivary hypersecretion.
ORZEYFUL is contraindicated in patients taking strong CYP3A inhibitors. Use with strong or moderate CYP3A inhibitors increases oveporexton exposure and may raise adverse-reaction risk. Strong and moderate CYP3A inducers may lower plasma levels and reduce effectiveness. Severe hepatic impairment (Child-Pugh C) and severe renal impairment on dialysis (eGFR below 15 mL/minute) should be avoided because those groups have not been studied.
What Comes Next After the Takeda ORZEYFUL Launch: Takeda’s Orexin Franchise
Beyond the Takeda ORZEYFUL launch, Takeda calls itself the leader in orexin science and positions ORZEYFUL as the lead asset in its orexin franchise. The company is also investigating other oral orexin agonists, including TAK-360 for NT1, narcolepsy type 2 and idiopathic hypersomnia, as well as TAK-495. These programs remain investigational.
On diagnosis, Takeda says it is working on biomarker solutions and digital tools that could support earlier identification and differentiation of NT1. No timelines were given, and any benefit is prospective and subject to development risk.
